Ajian Li1, Hui Chen2, Moubin Lin1, Chenbo Zhang1, Erjiang Tang3, Jian Peng4, Qing Wei5, Huaguang Li3, Lu Yin1. 1. Department of General Surgery, Ruijin Hospital Affiliated Shanghai Jiaotong University School of Medicine Shanghai 200025, China. 2. Department of General Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 200437, China. 3. Department of General Surgery, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200090, China. 4. Center for Translational Medicine, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200090, China. 5. Department of Pathology, The Tenth People's Hospital Affiliated to Shanghai Tongji University School of Medicine Shanghai 200072, China.
Abstract
PURPOSE: To investigate whether the copy number of PIK3C2G is associated with clinical outcomes for stage III colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy. METHODS: A total of 142 CRC patients who received first-line oxaliplatin-based chemotherapy after curative surgery in Ruijin Hospital and The Tenth People's Hospital were recruited in this study. Patients were enrolled between June 2006 and December 2011, with follow-up to January 2014. Quantitative real-time PCR method was used to detect the copy number of PIK3C2G. Cox proportional hazards model and Kaplan-Meier curves were used to analyze the association between PIK3C2G copy number and clinical outcome. RESULTS: In patients with stage III disease, low copy number of PIK3C2G was associated with increased risk of both recurrence (HR, 2.44, 95% CI, 1.33-4.47, P=0.004) and death (HR, 2.89, 95% CI, 1.49-5.60, P=0.002). Multivariate analysis also indicated that low PIK3C2G copy number was a significant and independent predictor of OS and RFS of stage III CRC. CONCLUSIONS: PIK3C2G is capable of predicting the recurrence and overall survival of stage III CRC patients receiving oxaliplatin-based therapy.
PURPOSE: To investigate whether the copy number of PIK3C2G is associated with clinical outcomes for stage III colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy. METHODS: A total of 142 CRCpatients who received first-line oxaliplatin-based chemotherapy after curative surgery in Ruijin Hospital and The Tenth People's Hospital were recruited in this study. Patients were enrolled between June 2006 and December 2011, with follow-up to January 2014. Quantitative real-time PCR method was used to detect the copy number of PIK3C2G. Cox proportional hazards model and Kaplan-Meier curves were used to analyze the association between PIK3C2G copy number and clinical outcome. RESULTS: In patients with stage III disease, low copy number of PIK3C2G was associated with increased risk of both recurrence (HR, 2.44, 95% CI, 1.33-4.47, P=0.004) and death (HR, 2.89, 95% CI, 1.49-5.60, P=0.002). Multivariate analysis also indicated that low PIK3C2G copy number was a significant and independent predictor of OS and RFS of stage III CRC. CONCLUSIONS:PIK3C2G is capable of predicting the recurrence and overall survival of stage III CRCpatients receiving oxaliplatin-based therapy.
Authors: Christian P Kratz; Brooke M Emerling; Jeannette Bonifas; Winfred Wang; Eric D Green; Michelle M Le Beau; Kevin M Shannon Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: Y Y Ma; S J Wei; Y C Lin; J C Lung; T C Chang; J Whang-Peng; J M Liu; D M Yang; W K Yang; C Y Shen Journal: Oncogene Date: 2000-05-25 Impact factor: 9.867
Authors: Theodore Nicolaides; Jean M Mulcahy Levy; Karisa C Schreck; Andrew Morin; Guisheng Zhao; Amy N Allen; Patrick Flannery; Michael Glantz; Adam L Green; Chris Jones; Kenneth L Jones; Lindsay B Kilburn; Kellie J Nazemi; David Samuel; Bridget Sanford; David A Solomon; Jiawan Wang; Christine A Pratilas Journal: Clin Cancer Res Date: 2021-08-25 Impact factor: 12.531
Authors: Jing-Jing Lu; Min-Bin Chen; Xiao-Jiao Gao; Yan Zhang; Yuan-Yuan Liu; Yang Yong; Ping Li Journal: J Int Med Res Date: 2022-03 Impact factor: 1.671